CERO Therapeutics Holdings, Inc. announced on March 19, 2025, an agreement with the University of California Davis for the manufacturing of CER-1236. This manufacturing will support the company’s upcoming Phase 1 clinical trial for Acute Myeloid Leukemia (AML).
The agreement with UC Davis, a leading institution with a strong reputation in manufacturing precision and compliance, is a crucial step in the clinical development process. CEO Chris Ehrlich emphasized that the manufacturing of the product is among the final steps required before patient dosing can commence.
CERO Therapeutics stated that it remains on track for dosing the first patient in the first half of 2025. This manufacturing partnership is vital for ensuring the timely and compliant production of CER-1236 for the clinical trial.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.